Class I transactivator, NLRC5: a central player in the MHC class I pathway and cancer immune surveillance

Saptha Vijayan, Tabasum Sidiq, Suhail Yousuf, Peter J. van den Elsen, Koichi S. Kobayashi

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

Major histocompatibility complex (MHC) class I and class II molecules play critical roles in the activation of the adaptive immune system by presenting antigens to CD8+ and CD4+ T cells, respectively. Although it has been well known that CIITA (MHC class II transactivator), an NLR (nucleotide-binding domain, leucine-rich-repeat containing) protein, as a master regulator of MHC class II gene expression, the mechanism of MHC class I gene transactivation was unclear. Recently, another NLR protein, NLRC5 (NLR family, CARD domain-containing 5), was identified as an MHC class I transactivator (CITA). NLRC5 is a critical regulator for the transcriptional activation of MHC class I genes and other genes involved in the MHC class I antigen presentation pathway. CITA/NLRC5 plays a crucial role in human cancer immunity through the recruitment and activation of tumor killing CD8+ T cells. Here, we discuss the molecular function and mechanism of CITA/NLRC5 in the MHC class I pathway and its role in cancer.
Original languageEnglish
Pages (from-to)273-282
JournalImmunogenetics
Volume71
Issue number3
DOIs
Publication statusPublished - 2019

Cite this

Vijayan, Saptha ; Sidiq, Tabasum ; Yousuf, Suhail ; van den Elsen, Peter J. ; Kobayashi, Koichi S. / Class I transactivator, NLRC5: a central player in the MHC class I pathway and cancer immune surveillance. In: Immunogenetics. 2019 ; Vol. 71, No. 3. pp. 273-282.
@article{e31812ee85cd418db920a24e827ff6b7,
title = "Class I transactivator, NLRC5: a central player in the MHC class I pathway and cancer immune surveillance",
abstract = "Major histocompatibility complex (MHC) class I and class II molecules play critical roles in the activation of the adaptive immune system by presenting antigens to CD8+ and CD4+ T cells, respectively. Although it has been well known that CIITA (MHC class II transactivator), an NLR (nucleotide-binding domain, leucine-rich-repeat containing) protein, as a master regulator of MHC class II gene expression, the mechanism of MHC class I gene transactivation was unclear. Recently, another NLR protein, NLRC5 (NLR family, CARD domain-containing 5), was identified as an MHC class I transactivator (CITA). NLRC5 is a critical regulator for the transcriptional activation of MHC class I genes and other genes involved in the MHC class I antigen presentation pathway. CITA/NLRC5 plays a crucial role in human cancer immunity through the recruitment and activation of tumor killing CD8+ T cells. Here, we discuss the molecular function and mechanism of CITA/NLRC5 in the MHC class I pathway and its role in cancer.",
author = "Saptha Vijayan and Tabasum Sidiq and Suhail Yousuf and {van den Elsen}, {Peter J.} and Kobayashi, {Koichi S.}",
year = "2019",
doi = "10.1007/s00251-019-01106-z",
language = "English",
volume = "71",
pages = "273--282",
journal = "Immunogenetics",
issn = "0093-7711",
publisher = "Springer Verlag",
number = "3",

}

Class I transactivator, NLRC5: a central player in the MHC class I pathway and cancer immune surveillance. / Vijayan, Saptha; Sidiq, Tabasum; Yousuf, Suhail; van den Elsen, Peter J.; Kobayashi, Koichi S.

In: Immunogenetics, Vol. 71, No. 3, 2019, p. 273-282.

Research output: Contribution to journalReview articleAcademicpeer-review

TY - JOUR

T1 - Class I transactivator, NLRC5: a central player in the MHC class I pathway and cancer immune surveillance

AU - Vijayan, Saptha

AU - Sidiq, Tabasum

AU - Yousuf, Suhail

AU - van den Elsen, Peter J.

AU - Kobayashi, Koichi S.

PY - 2019

Y1 - 2019

N2 - Major histocompatibility complex (MHC) class I and class II molecules play critical roles in the activation of the adaptive immune system by presenting antigens to CD8+ and CD4+ T cells, respectively. Although it has been well known that CIITA (MHC class II transactivator), an NLR (nucleotide-binding domain, leucine-rich-repeat containing) protein, as a master regulator of MHC class II gene expression, the mechanism of MHC class I gene transactivation was unclear. Recently, another NLR protein, NLRC5 (NLR family, CARD domain-containing 5), was identified as an MHC class I transactivator (CITA). NLRC5 is a critical regulator for the transcriptional activation of MHC class I genes and other genes involved in the MHC class I antigen presentation pathway. CITA/NLRC5 plays a crucial role in human cancer immunity through the recruitment and activation of tumor killing CD8+ T cells. Here, we discuss the molecular function and mechanism of CITA/NLRC5 in the MHC class I pathway and its role in cancer.

AB - Major histocompatibility complex (MHC) class I and class II molecules play critical roles in the activation of the adaptive immune system by presenting antigens to CD8+ and CD4+ T cells, respectively. Although it has been well known that CIITA (MHC class II transactivator), an NLR (nucleotide-binding domain, leucine-rich-repeat containing) protein, as a master regulator of MHC class II gene expression, the mechanism of MHC class I gene transactivation was unclear. Recently, another NLR protein, NLRC5 (NLR family, CARD domain-containing 5), was identified as an MHC class I transactivator (CITA). NLRC5 is a critical regulator for the transcriptional activation of MHC class I genes and other genes involved in the MHC class I antigen presentation pathway. CITA/NLRC5 plays a crucial role in human cancer immunity through the recruitment and activation of tumor killing CD8+ T cells. Here, we discuss the molecular function and mechanism of CITA/NLRC5 in the MHC class I pathway and its role in cancer.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85060873914&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/30706093

U2 - 10.1007/s00251-019-01106-z

DO - 10.1007/s00251-019-01106-z

M3 - Review article

VL - 71

SP - 273

EP - 282

JO - Immunogenetics

JF - Immunogenetics

SN - 0093-7711

IS - 3

ER -